Acrivon Therapeutics Inc
(ACRV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 27,489 | 29,519 | 32,080 | 0 | 0 |
| Marketable Securities | 92,723 | 98,232 | 44,743 | 0 | 0 |
| TOTAL | $123,963 | $132,095 | $78,672 | $0 | $0 |
| Non-Current Assets | |||||
| PPE Net | 1,992 | 2,092 | 2,151 | N/A | N/A |
| Investments And Advances | 39,275 | 41,881 | 0 | 0 | 0 |
| Other Non-Current Assets | 4,967 | 5,158 | 6,890 | 0 | 0 |
| TOTAL | $46,234 | $49,131 | $9,041 | $N/A | $N/A |
| Total Assets | $170,197 | $181,226 | $87,713 | $0 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,374 | 904 | 1,976 | 0 | 0 |
| Accrued Expenses | 3,568 | 4,886 | 3,698 | 0 | 0 |
| TOTAL | $5,682 | $6,516 | $6,391 | $0 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 4,046 | 4,235 | 4,420 | 0 | 0 |
| TOTAL | $4,046 | $4,235 | $4,420 | $N/A | $N/A |
| Total Liabilities | $9,728 | $10,751 | $10,811 | $0 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 21,926 | 21,921 | 20,885 | N/A | N/A |
| Common Shares | 22 | 22 | 2 | 0 | 0 |
| Retained earnings | -68,788 | -56,032 | -47,103 | 0 | 0 |
| Other shareholders' equity | 9 | -95 | 122,385 | 0 | 0 |
| TOTAL | $160,469 | $170,475 | $76,902 | $0 | $0 |
| Total Liabilities And Equity | $170,197 | $181,226 | $87,713 | $0 | $0 |